Developer docs
API playgroundTry for free, no card

Search company profiles

NovAliX

Full company profile

uuid0003ih8

Namestring
NovAliX
Legal namestring
Novalix SAS
Websiteurl
novalix.com
Company typeenum
Private
Founded yearint
2002
Descriptiontext

NovAliX is a privately held, France-headquartered preclinical contract research organization founded in 2002 that provides integrated drug discovery services to biotechnology and pharmaceutical companies. The company operates five service platforms: Novalead (chemistry and DNA-encoded libraries), Novalens (biophysics), Novalink (pharmacology and DMPK), Novalaunch (integrated drug discovery programs), and Novaluxe (cosmetics). Service delivery spans hit identification, medicinal chemistry, structural biology (Cryo-EM, X-ray crystallography, NMR), biophysics (SPR, mass spectrometry, switchSENSE), ADME-PK and preformulation, in vivo pharmacology across oncology, immuno-inflammation, fibrosis, kidney disease, metabolic disorders, infectious diseases, and osteoarthritis, plus biobank and histology services. Equipment assets include Bruker ultra-high-field NMR (600 MHz to 1 GHz), Cryo-EM Glacios and Titan Krios microscopes with Falcon4i detectors, an in-house HPC cluster with 20 NVIDIA GPUs, and monthly privileged synchrotron access at SOLEIL. Reported outputs include 62 drug candidates developed or supported, 1,000+ solved crystal structures, 600+ structures across 130+ proteins, and peer-reviewed publications in journals such as Nature, ACS Medicinal Chemistry Letters, and Scientific Reports.

The company's business model is a professional services CRO with fee-for-service and full-time equivalent contracts complemented by research and milestone fees, plus alternative structures including technology transfer, maturation programs, and risk-sharing alliances with biotech, pharma, venture capital, and technology transfer offices. Distribution is direct enterprise sales through outsourcing and co-located insourcing models, supported by major industry events (BIO International Convention 2026) and scientific webinars. Geographic footprint spans four French sites (Strasbourg HQ, Romainville, Gif-sur-Yvette, Val-de-Reuil), a US biophysics operation inside Bruker's Demo Lab in Billerica, Massachusetts, and an international site in Sidi Thabet, Tunisia. Strategic partnerships include a minority investment by Bruker (August 2024), a long-term collaboration with the Max Planck Institute for Multidisciplinary Sciences (March 2024, with MPI scientists embedded in Strasbourg), and the PIPAc consortium (Bruker, NovAliX, Alysophil, De Dietrich Process Systems) developing AI-driven autonomous continuous manufacturing for pharmaceutical APIs. The workforce is reported at 430+ colleagues with 100% scientific teams holding prior pharma industry experience.

AI/ML is a differentiated capability layered across the platform, centered on the proprietary NovaDEL DNA-encoded library with integrated machine learning models, generative AI for hit expansion, AI-driven cheminformatics for potency and ADME prediction, AI-based histology quantification (Visiopharm), and AI-assisted 3D protein structure determination (ARTINA). The company's cheminformatics team has achieved top rankings in major international blind challenges, including #1 in the ASAP Discovery–Polaris–OpenADMET Antiviral Challenge and #1 in ROC-AUC in the DREAM Target 2035 Drug Discovery Challenge. Ownership remains with executive management, scientific founders, and employees following the Bruker minority investment, and the company operates as Novalix SAS under French law.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersStrasbourg, France
HQ citystring
Strasbourg
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices6 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
drug discovery services, preclinical contract research, biophysics characterization services, DNA-encoded library screening, pharmacology ADME services
Industry1 code
PRIMARYHLAGAAAB
Preclinical CROs (Discovery/Pharmacology/DMPK)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Research and Development in the Physical, Engineering, and Life Sciences54171
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Preclinical Drug Discovery Services (Contract Research Organization)
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Fee-for-Service Research Contracts
TypeProfessional Services
Description

Novalix provides research services on a fee-for-service and full-time equivalent (FTE) basis, including research and milestone fees. This is the primary revenue model for the CRO.

novalix.com
2Risk-Sharing Alliances and Alternative Commercial Structures
TypeManaged Services
Description

Novalix considers alternative commercial structures including technology transfer, maturation programs, and risk-sharing alliances with diverse partners including biotechnology companies, pharmaceutical corporations, venture capital firms, and technology transfer offices (TTOs).

novalix.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales
Pricing details1 tier
1Fee-for-service and full-time equivalent basis
ModelOtherBilling cadenceMulti-year contract
Notes

Research and milestone fees. No publicly listed pricing; custom quotes based on project scope.

novalix.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 6 records shown
1Novalead
Description

Chemistry services platform for compound refinement and optimization using proprietary DNA-encoded library resources.

novalix.com
+5 more records
Core offering1 text field

NovAliX is a preclinical contract research organization (CRO) providing integrated drug discovery services to biotechnology and pharmaceutical companies across five service platforms: Novalead (chemistry and proprietary DNA-encoded libraries), Novalens (biophysics — Cryo-EM, X-ray, NMR, SPR, MS, switchSENSE), Novalink (pharmacology and DMPK), Novalaunch (drug discovery), and Novaluxe (cosmetics). Services are delivered through outsourcing, insourcing, and risk-sharing engagement models on a fee-for-service and FTE basis.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Top performer in global AI/ML drug discovery competitions — ranked #1 in IC50 prediction for SARS-CoV-2 Mpro and #4 in aggregated ADME among 65+ teams (Polaris Antiviral Challenge)
+3 more records
Product overview1 text field

NovAliX is a premier preclinical Contract Research Organization (CRO) offering an integrated drug discovery platform across three core service pillars — Chemistry (Novalead), Biophysics (Novalens), and Pharmacology/DMPK (Novalink) — coordinated through its Drug Discovery division (Novalaunch). The company operates a modular portfolio of specialized services including DNA-Encoded Libraries (NovaDEL with integrated AI-ML pipeline), X-ray crystallography, Cryo-EM (with Max Planck partnership), NMR (with Bruker ultra-high-field instruments and AI-driven ARTINA software), SPR, mass spectrometry, switchSENSE technology (Bruker heliX+), and comprehensive in vivo pharmacology models across oncology, immuno-inflammation, fibrosis, kidney diseases, metabolic disorders, infectious diseases, and osteoarthritis. The company also applies its drug discovery expertise to cosmetics through the Novaluxe brand. NovAliX offers multiple collaborative engagement models (outsourcing, insourcing, and risk-sharing alliances) and delivers services primarily as a fee-for-service and full-time equivalent CRO, with over 430 employees across France (Strasbourg, Romainville, Gif-sur-Yvette, Val-de-Reuil) and the US (Billerica, Massachusetts).

Product and service9 records
1Chemistry Services (Novalead)
CategoryDrug Discovery CRO Services - Chemistry
Description

Expert chemistry services refining and purifying compounds for biotech and pharmaceutical clients, leveraging a proprietary DNA-encoded library and capabilities spanning organometallic, heterocyclic, photo-/electro-chemistry, flow chemistry, PROTACs, and compound management.

2Biophysics Services (Novalens)
CategoryDrug Discovery CRO Services - Biophysics
Description

Comprehensive biophysics platform providing a complete view of molecules and interactions — characterization, binding, conformational change — using protein production, Cryo-EM, X-ray crystallography, NMR, SPR, mass spectrometry and switchSENSE technology, for biotech and pharma discovery programs.

3Pharmacology and DMPK Services (Novalink)
CategoryDrug Discovery CRO Services - Pharmacology / DMPK
Description

Custom pharmacology and DMPK solutions that connect preclinical efficacy with clinical success — biochemical assays, cellular and primary tissue assays, ADME-PK and preformulation, in vivo pharmacology, histology, biobank, and PK/PD — for biotech and pharma clients.

4Drug Discovery Services (Novalaunch)
CategoryDrug Discovery CRO Services - Integrated Programs
Description

Integrated drug discovery programs executed by senior scientists with big-pharma experience, combining medicinal chemistry, cheminformatics and DNA-encoded libraries to support early-stage biotech discovery projects across all internal platforms.

5Cosmetics Services (Novaluxe)
CategoryCRO Services - Cosmetics R&D
Description

Cosmetics discovery services using proven drug discovery expertise — custom testing, fragrances, flavors and ingredients, NMR analytics, in vitro assays and derma-filler solutions — for cosmetics manufacturers and brands.

6NovaDEL DNA-Encoded Library Platform
CategoryHit Identification Service - DNA-Encoded Libraries
Description

Proprietary DNA-encoded library screening service for hit identification and rapid lead generation, combining library design, QC, AI-driven DEL data analysis, ML DEL models and biophysical hit confirmation for biotech and pharma clients.

7Outsourcing Engagement Model
CategoryEngagement Model
Description

External project support model where clients collaborate with Novalix's senior scientists to strategize, execute and deliver drug discovery programs on a fee-for-service / FTE basis.

8Insourcing Engagement Model
CategoryEngagement Model
Description

Co-located engagement model where Novalix teams work in close proximity with a client's team in a streamlined environment, often coupled with outsourcing for capacity flexibility and operational efficiency.

9Risk-Sharing Alliances and Alternative Commercial Structures
CategoryEngagement Model
Description

Alternative commercial structures including technology transfer, maturation programs and risk-sharing alliances with biotechnology companies, pharmaceutical corporations, venture capital firms and technology transfer offices.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
1Max Planck Institute (MPI) for Multidisciplinary Sciences
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-03-05
Description

Long-term strategic partnership between Novalix and Max Planck Institute for Multidisciplinary Sciences in Göttingen, Germany. Max Planck scientists began operations in January 2024 at Novalix's Strasbourg research center to tackle oncology and anti-infective projects. The collaboration aims to make the translation of scientific research and academic insights into real therapies more efficient, combining Novalix's drug discovery expertise with MPI's Cryo-EM knowledge and exclusive next-generation image-refining software.

novalix.com
2PIPAc Consortium (Bruker, Novalix, Alysophil, De Dietrich Process Systems)
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Collaborative consortium developing an AI-driven autonomous continuous manufacturing platform for pharmaceutical API production, integrating continuous flow chemistry, in-line benchtop NMR spectroscopy, digital twin technology, and AI control systems. Validated using fentanyl and propofol workflows. Partners: Bruker, Novalix, Alysophil, and De Dietrich Process Systems.

news-medical.net
3COS Europe – Strasbourg School of Osteopathy
Strategic tierMinorTypeOthers
Description

Novalix partnered with COS Europe – Strasbourg School of Osteopathy during 2026 Workplace Well-Being Week (June 15-22) to offer employees individual osteopathy consultations at the school's teaching clinics, conducted by final-year students under experienced osteopath supervision.

novalix.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Evotec is a Hamburg-based integrated drug discovery CRO offering chemistry, biophysics, in vivo pharmacology, and DMPK with similar outsourcing/insourcing and risk-sharing models. Closest direct peer to NovAliX in scope and European footprint.

TypeBroad incumbent
Description

Much larger US-based preclinical CRO with discovery, safety assessment, and manufacturing services. Overlaps with NovAliX in early discovery and in vivo pharmacology but operates at substantially greater scale and global footprint.

TypeDirect peer
Description

China-headquartered full-service preclinical CRO with extensive chemistry, DMPK, and biology capabilities serving global biotech and pharma. Direct competitor for outsourced preclinical drug discovery projects.

TypeDirect peer
Description

UK-based preclinical CRO specializing in medicinal chemistry, DMPK, and in vivo pharmacology with strong drug discovery client base in Europe and US. Closely comparable in integrated medicinal chemistry + DMPK positioning.

TypeDirect peer
Description

China/US/UK-based preclinical CRO offering chemistry, biology, DMPK, and safety assessment. Direct competitor for integrated preclinical drug discovery outsourcing.

TypeDirect peer
Description

Poland-based CRO/CDMO offering medicinal chemistry, DMPK, and preclinical services with strong European biotech client base. Comparable scale and integrated discovery offering.

TypeBroad incumbent
Description

Discovery arm of Eurofins providing in vitro pharmacology, ADME, and screening services under a broader testing-services portfolio. Overlaps with NovAliX in assay, ADME, and biophysics but as part of a much larger testing platform.

TypeEmerging player
Description

UK-based preclinical CRO with integrated medicinal chemistry, structural biology (X-ray/cryo-EM), and DMPK services for small/medium biotech. Smaller than NovAliX but overlaps on integrated discovery and biophysics positioning.

9GVK Biosciences (Aragen Life Sciences)
TypeEmerging player
Description

India-based discovery CRO providing medicinal chemistry, DMPK, and biology services. Targets similar virtual and emerging biotech clients with cost-advantaged discovery outsourcing.

TypeEmerging player
Description

US-based computational drug discovery platform with AI/ML-driven FEP+ and LiveDesign; intersects with NovAliX's cheminformatics and AI-driven DEL capabilities rather than its wet-lab services, representing an emerging alternative approach to early discovery.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI capability12 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature9 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles19 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

NovAliX

Preclinical Drug Discovery Services (Contract Research Organization)novalix.com

What NovAliX does

NovAliX is a privately held, France-headquartered preclinical contract research organization founded in 2002 that provides integrated drug discovery services to biotechnology and pharmaceutical companies. The company operates five service platforms: Novalead (chemistry and DNA-encoded libraries), Novalens (biophysics), Novalink (pharmacology and DMPK), Novalaunch (integrated drug discovery programs), and Novaluxe (cosmetics). Service delivery spans hit identification, medicinal chemistry, structural biology (Cryo-EM, X-ray crystallography, NMR), biophysics (SPR, mass spectrometry, switchSENSE), ADME-PK and preformulation, in vivo pharmacology across oncology, immuno-inflammation, fibrosis, kidney disease, metabolic disorders, infectious diseases, and osteoarthritis, plus biobank and histology services. Equipment assets include Bruker ultra-high-field NMR (600 MHz to 1 GHz), Cryo-EM Glacios and Titan Krios microscopes with Falcon4i detectors, an in-house HPC cluster with 20 NVIDIA GPUs, and monthly privileged synchrotron access at SOLEIL. Reported outputs include 62 drug candidates developed or supported, 1,000+ solved crystal structures, 600+ structures across 130+ proteins, and peer-reviewed publications in journals such as Nature, ACS Medicinal Chemistry Letters, and Scientific Reports.

The company's business model is a professional services CRO with fee-for-service and full-time equivalent contracts complemented by research and milestone fees, plus alternative structures including technology transfer, maturation programs, and risk-sharing alliances with biotech, pharma, venture capital, and technology transfer offices. Distribution is direct enterprise sales through outsourcing and co-located insourcing models, supported by major industry events (BIO International Convention 2026) and scientific webinars. Geographic footprint spans four French sites (Strasbourg HQ, Romainville, Gif-sur-Yvette, Val-de-Reuil), a US biophysics operation inside Bruker's Demo Lab in Billerica, Massachusetts, and an international site in Sidi Thabet, Tunisia. Strategic partnerships include a minority investment by Bruker (August 2024), a long-term collaboration with the Max Planck Institute for Multidisciplinary Sciences (March 2024, with MPI scientists embedded in Strasbourg), and the PIPAc consortium (Bruker, NovAliX, Alysophil, De Dietrich Process Systems) developing AI-driven autonomous continuous manufacturing for pharmaceutical APIs. The workforce is reported at 430+ colleagues with 100% scientific teams holding prior pharma industry experience.

AI/ML is a differentiated capability layered across the platform, centered on the proprietary NovaDEL DNA-encoded library with integrated machine learning models, generative AI for hit expansion, AI-driven cheminformatics for potency and ADME prediction, AI-based histology quantification (Visiopharm), and AI-assisted 3D protein structure determination (ARTINA). The company's cheminformatics team has achieved top rankings in major international blind challenges, including #1 in the ASAP Discovery–Polaris–OpenADMET Antiviral Challenge and #1 in ROC-AUC in the DREAM Target 2035 Drug Discovery Challenge. Ownership remains with executive management, scientific founders, and employees following the Bruker minority investment, and the company operates as Novalix SAS under French law.

NovAliX firmographics

Firmographics
Name
NovAliX
Legal name
Novalix SAS
Website
https://novalix.com
Company type
Private
Founded year
2002
Operating status
Operating
Headcount range
251–500 employees
Ownership category
akta.pro rank

NovAliX industry classification

Industry
Product category
Preclinical Drug Discovery Services (Contract Research Organization)
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAAAB
Preclinical CROs (Discovery/Pharmacology/DMPK)

Keywords

  • Drug discovery services
  • Preclinical contract research
  • Biophysics characterization services
  • DNA-encoded library screening
  • Pharmacology ADME services

Where NovAliX is headquartered

Location

Headquarters

HQ city
Strasbourg
HQ country
France
HQ region
Europe

Offices6 records

Markets served

NovAliX business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales

Revenue model

  1. Fee-for-Service Research Contracts: Novalix provides research services on a fee-for-service and full-time equivalent (FTE) basis, including research and milestone fees. This is the primary revenue model for the CRO.
  2. Risk-Sharing Alliances and Alternative Commercial Structures: Novalix considers alternative commercial structures including technology transfer, maturation programs, and risk-sharing alliances with diverse partners including biotechnology companies, pharmaceutical corporations, venture capital firms, and technology transfer offices (TTOs).

Pricing tiers

ModelBillingPrice
OtherMulti-year contractFee-for-service and full-time equivalent basis

Go-to-market motion2 records

Distribution channels4 records

Marketing channels6 records

NovAliX product offering

Product offering

Core offering

NovAliX is a preclinical contract research organization (CRO) providing integrated drug discovery services to biotechnology and pharmaceutical companies across five service platforms: Novalead (chemistry and proprietary DNA-encoded libraries), Novalens (biophysics — Cryo-EM, X-ray, NMR, SPR, MS, switchSENSE), Novalink (pharmacology and DMPK), Novalaunch (drug discovery), and Novaluxe (cosmetics). Services are delivered through outsourcing, insourcing, and risk-sharing engagement models on a fee-for-service and FTE basis.

Product overview

NovAliX is a premier preclinical Contract Research Organization (CRO) offering an integrated drug discovery platform across three core service pillars — Chemistry (Novalead), Biophysics (Novalens), and Pharmacology/DMPK (Novalink) — coordinated through its Drug Discovery division (Novalaunch). The company operates a modular portfolio of specialized services including DNA-Encoded Libraries (NovaDEL with integrated AI-ML pipeline), X-ray crystallography, Cryo-EM (with Max Planck partnership), NMR (with Bruker ultra-high-field instruments and AI-driven ARTINA software), SPR, mass spectrometry, switchSENSE technology (Bruker heliX+), and comprehensive in vivo pharmacology models across oncology, immuno-inflammation, fibrosis, kidney diseases, metabolic disorders, infectious diseases, and osteoarthritis. The company also applies its drug discovery expertise to cosmetics through the Novaluxe brand. NovAliX offers multiple collaborative engagement models (outsourcing, insourcing, and risk-sharing alliances) and delivers services primarily as a fee-for-service and full-time equivalent CRO, with over 430 employees across France (Strasbourg, Romainville, Gif-sur-Yvette, Val-de-Reuil) and the US (Billerica, Massachusetts).

Differentiator

Problem solved

Functional benefit

Brands

  • Novalead: Chemistry services platform for compound refinement and optimization using proprietary DNA-encoded library resources.
  • Novalens
  • Novalink
  • Novalaunch
  • Novaluxe
  • NovaDEL

Products and services

  • Chemistry Services (Novalead) Expert chemistry services refining and purifying compounds for biotech and pharmaceutical clients, leveraging a proprietary DNA-encoded library and capabilities spanning organometallic, heterocyclic, photo-/electro-chemistry, flow chemistry, PROTACs, and compound management.
  • Biophysics Services (Novalens) Comprehensive biophysics platform providing a complete view of molecules and interactions — characterization, binding, conformational change — using protein production, Cryo-EM, X-ray crystallography, NMR, SPR, mass spectrometry and switchSENSE technology, for biotech and pharma discovery programs.
  • Pharmacology and DMPK Services (Novalink) Custom pharmacology and DMPK solutions that connect preclinical efficacy with clinical success — biochemical assays, cellular and primary tissue assays, ADME-PK and preformulation, in vivo pharmacology, histology, biobank, and PK/PD — for biotech and pharma clients.
  • Drug Discovery Services (Novalaunch) Integrated drug discovery programs executed by senior scientists with big-pharma experience, combining medicinal chemistry, cheminformatics and DNA-encoded libraries to support early-stage biotech discovery projects across all internal platforms.
  • Cosmetics Services (Novaluxe) Cosmetics discovery services using proven drug discovery expertise — custom testing, fragrances, flavors and ingredients, NMR analytics, in vitro assays and derma-filler solutions — for cosmetics manufacturers and brands.
  • NovaDEL DNA-Encoded Library Platform Proprietary DNA-encoded library screening service for hit identification and rapid lead generation, combining library design, QC, AI-driven DEL data analysis, ML DEL models and biophysical hit confirmation for biotech and pharma clients.
  • Outsourcing Engagement Model External project support model where clients collaborate with Novalix's senior scientists to strategize, execute and deliver drug discovery programs on a fee-for-service / FTE basis.
  • Insourcing Engagement Model Co-located engagement model where Novalix teams work in close proximity with a client's team in a streamlined environment, often coupled with outsourcing for capacity flexibility and operational efficiency.
  • Risk-Sharing Alliances and Alternative Commercial Structures Alternative commercial structures including technology transfer, maturation programs and risk-sharing alliances with biotechnology companies, pharmaceutical corporations, venture capital firms and technology transfer offices.

Quantifiable outcome

  • Top performer in global AI/ML drug discovery competitions — ranked #1 in IC50 prediction for SARS-CoV-2 Mpro and #4 in aggregated ADME among 65+ teams (Polaris Antiviral Challenge)
  • +3 more outcomes

Companies that use NovAliX

Customer profile

Named customers2 records

Segments2 records

Ideal customer profiles2 records

NovAliX technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability12 records

Feature9 records

NovAliX partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and minor.

  • Max Planck Institute (MPI) for Multidisciplinary SciencescoreStrategic or Co-development Partner · 5 March 2024Long-term strategic partnership between Novalix and Max Planck Institute for Multidisciplinary Sciences in Göttingen, Germany. Max Planck scientists began operations in January 2024 at Novalix's Strasbourg research center to tackle oncology and anti-infective projects. The collaboration aims to make the translation of scientific research and academic insights into real therapies more efficient, combining Novalix's drug discovery expertise with MPI's Cryo-EM knowledge and exclusive next-generation image-refining software.
  • PIPAc Consortium (Bruker, Novalix, Alysophil, De Dietrich Process Systems)minorStrategic or Co-development PartnerCollaborative consortium developing an AI-driven autonomous continuous manufacturing platform for pharmaceutical API production, integrating continuous flow chemistry, in-line benchtop NMR spectroscopy, digital twin technology, and AI control systems. Validated using fentanyl and propofol workflows. Partners: Bruker, Novalix, Alysophil, and De Dietrich Process Systems.
  • COS Europe – Strasbourg School of OsteopathyminorOthersNovalix partnered with COS Europe – Strasbourg School of Osteopathy during 2026 Workplace Well-Being Week (June 15-22) to offer employees individual osteopathy consultations at the school's teaching clinics, conducted by final-year students under experienced osteopath supervision.

Scale indicators7 records

Recent moves6 records

Expansion highlights7 records

NovAliX competitors and assessment

Company assessment

Direct peers

  • Evotec: Evotec is a Hamburg-based integrated drug discovery CRO offering chemistry, biophysics, in vivo pharmacology, and DMPK with similar outsourcing/insourcing and risk-sharing models. Closest direct peer to NovAliX in scope and European footprint.
  • WuXi AppTec: China-headquartered full-service preclinical CRO with extensive chemistry, DMPK, and biology capabilities serving global biotech and pharma. Direct competitor for outsourced preclinical drug discovery projects.
  • Sygnature Discovery: UK-based preclinical CRO specializing in medicinal chemistry, DMPK, and in vivo pharmacology with strong drug discovery client base in Europe and US. Closely comparable in integrated medicinal chemistry + DMPK positioning.
  • Pharmaron: China/US/UK-based preclinical CRO offering chemistry, biology, DMPK, and safety assessment. Direct competitor for integrated preclinical drug discovery outsourcing.
  • Selvita: Poland-based CRO/CDMO offering medicinal chemistry, DMPK, and preclinical services with strong European biotech client base. Comparable scale and integrated discovery offering.

Broad incumbents

  • Charles River Laboratories: Much larger US-based preclinical CRO with discovery, safety assessment, and manufacturing services. Overlaps with NovAliX in early discovery and in vivo pharmacology but operates at substantially greater scale and global footprint.
  • Eurofins Discovery: Discovery arm of Eurofins providing in vitro pharmacology, ADME, and screening services under a broader testing-services portfolio. Overlaps with NovAliX in assay, ADME, and biophysics but as part of a much larger testing platform.

Emerging players

  • Domainex: UK-based preclinical CRO with integrated medicinal chemistry, structural biology (X-ray/cryo-EM), and DMPK services for small/medium biotech. Smaller than NovAliX but overlaps on integrated discovery and biophysics positioning.
  • GVK Biosciences (Aragen Life Sciences): India-based discovery CRO providing medicinal chemistry, DMPK, and biology services. Targets similar virtual and emerging biotech clients with cost-advantaged discovery outsourcing.
  • Schrödinger: US-based computational drug discovery platform with AI/ML-driven FEP+ and LiveDesign; intersects with NovAliX's cheminformatics and AI-driven DEL capabilities rather than its wet-lab services, representing an emerging alternative approach to early discovery.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

NovAliX social profiles

Digital presence

NovAliX compliance and trust

Trust signal

Compliance1 record

NovAliX financial estimates

Financial estimate

Revenue estimate

Valuation estimate

NovAliX leadership team

Management profile

Number of profiles

Profiles19 records

NovAliX funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

NovAliX M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NovAliX

What does NovAliX do?

NovAliX is a preclinical contract research organization (CRO) providing integrated drug discovery services to biotechnology and pharmaceutical companies across five service platforms: Novalead (chemistry and proprietary DNA-encoded libraries), Novalens (biophysics — Cryo-EM, X-ray, NMR, SPR, MS, switchSENSE), Novalink (pharmacology and DMPK), Novalaunch (drug discovery), and Novaluxe (cosmetics). Services are delivered through outsourcing, insourcing, and risk-sharing engagement models on a fee-for-service and FTE basis.

Is NovAliX a public or private company?

NovAliX is a private company. It is classified as management employee owned and is currently operating.

When was NovAliX founded?

NovAliX was founded in 2002. It employs 251 to 500 people.

Where is NovAliX based?

NovAliX is headquartered in Strasbourg, France, in the Europe region.

How does NovAliX make money?

Two revenue lines are on record. Fee-for-Service Research Contracts are the primary driver. The others are risk-Sharing Alliances and Alternative Commercial Structures.

Who are NovAliX's main competitors?

Direct peers on record are Evotec, WuXi AppTec, Sygnature Discovery, Pharmaron and Selvita. Broad incumbents are Charles River Laboratories and Eurofins Discovery. Emerging players are Domainex, GVK Biosciences (Aragen Life Sciences) and Schrödinger.

Does NovAliX have an API?

No public API is recorded for NovAliX.

What industry is NovAliX in?

NovAliX's product category is Preclinical Drug Discovery Services (Contract Research Organization). Its primary akta.pro industry code is HLAGAAAB, Preclinical CROs (Discovery/Pharmacology/DMPK). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceNovalix and OpenBench Partner to Create Fee-For-Success Drug Discovery for Life Science OrganizationsNovalix and OpenBench announced a partnership to deliver experimentally validated chemical hit series via a fee-for-success model. OpenBench screens compounds and synthesizes hits, while Novalix performs in vitro screening, with clients paying only when validated hits are delivered. The workflow can deliver validated hit series in as little as six months.PrtimesiBodyとNovalix Japanが業務提携iBody and Novalix Japan signed a business partnership to strengthen antibody drug discovery support. The deal combines iBody's antibody discovery technology with Novalix's evaluation and global network. The partnership aims to provide higher-value drug discovery solutions to pharmaceutical companies.News-MedicalHow to implement autonomous continuous processing for modern API manufacturingThis article describes an AI-driven autonomous continuous manufacturing platform developed by the PIPAc consortium (Bruker, Novalix, Alysophil, and De Dietrich Process Systems) that integrates continuous flow chemistry, in-line benchtop NMR spectroscopy, digital twin technology, and AI control systems for pharmaceutical API production. The platform was validated using fentanyl and propofol workflows, demonstrating real-time monitoring, adaptive optimization, and a compact footprint suitable for on-demand manufacturing. The article functions as a technical overview promoting this modular system designed to support more resilient, just-in-time pharmaceutical production aligned with Pharma 4.0 principles.openPR.comMarket Trend Analysis: The Impact of Emerging Developments on the Small Molecule Active Pharmaceutical Ingredient MarketThe Business Research Company projects the small molecule active pharmaceutical ingredient (API) market will reach $278.85 billion by 2029, growing at a 7.6% CAGR driven by precision medicine and AI integration. A key industry development includes Pharmaron Beijing's acquisition of Recipharm's API manufacturing facility to expand its production capabilities. The report also highlights strategic collaborations, such as those involving NovAliX and Bruker, aimed at developing innovative manufacturing solutions.ContractpharmaDrug Discovery CRO NovAliX Partners with Instrument Provider BrukerNovAliX, a drug discovery CRO, announced a strategic alliance with Bruker, with Bruker taking a minority ownership stake. The partnership aims to accelerate biophysical methods and establish the Biophysics Institute for Biomedical Research (IBRB) to foster innovation.YahooBruker (BRKR) Partners With NovAliX to Boost Drug DiscoveryBruker announced a partnership with NovAliX to accelerate drug discovery using biophysical technologies. The collaboration targets target identification and drug candidate optimization, with a new Biophysics Institute opening in 2026. The drug discovery market is projected to grow from $111.48 billion in 2023 to $192.2 billion by 2032.FinSMEsNovAliX Receives Investment from BrukerNovAliX, a Strasbourg-based preclinical CRO, received an undisclosed investment from Bruker. The company will use the funds to accelerate growth, particularly in Europe and the US. Bruker and NovAliX plan to open a joint Biophysics Institute in Strasbourg in 2026.Financial TimesBruker Announces Strategic Minority Investment in NovAliX – Company AnnouncementBruker announced a strategic minority investment in NovAliX, a preclinical CRO, to accelerate its growth in Europe and the US. The partnership will leverage Bruker's biophysical methods, especially NMR, for drug discovery. A joint Biophysics Institute in Strasbourg is planned to open in 2026.TmcnetBruker Announces Strategic Minority Investment in NovAliXBruker announced a strategic minority investment in NovAliX, a preclinical CRO in Strasbourg, France, to accelerate its growth in Europe and the U.S. The partnership will leverage Bruker's biophysical technologies, including NMR, to advance drug discovery methods. A joint Biophysics Institute is planned to open in 2026.ContractpharmaNovAliX Partners with MPI to Advance Drug DiscoveryNovAliX and the Max Planck Institute for Multidisciplinary Sciences announced a partnership to accelerate drug discovery by integrating academic research into development. The collaboration aims to bridge the gap between fundamental research and early-stage drug discovery, with both leaders citing the need for deeper academic involvement to improve success odds.